The lncRNA leucine-rich repeat containing 75 A-antisense RNA1 (LRRC75A-AS1) was identified through lncRNA microarray as a potential lncRNA that may predict the efficacy of immune checkpoint inhibitor therapy and cancer progression in RCC. Here, LRRC75A is linked to renal cell carcinoma.